These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 11912378)

  • 21. Intravesical bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell carcinoma of the bladder: recurrence, progression and survival in a study of 57 patients.
    Peyromaure M; Guerin F; Amsellem-Ouazana D; Saighi D; Debre B; Zerbib M
    J Urol; 2003 Jun; 169(6):2110-2. PubMed ID: 12771729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
    Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
    BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk factors for upper tract recurrence in patients undergoing long-term surveillance for stage ta bladder cancer.
    Canales BK; Anderson JK; Premoli J; Slaton JW
    J Urol; 2006 Jan; 175(1):74-7. PubMed ID: 16406874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reproducibility and prognostic variability of grade and lamina propria invasion in stages Ta, T1 urothelial carcinoma of the bladder.
    Bol MG; Baak JP; Buhr-Wildhagen S; Kruse AJ; Kjellevold KH; Janssen EA; Mestad O; Øgreid P
    J Urol; 2003 Apr; 169(4):1291-4. PubMed ID: 12629345
    [TBL] [Abstract][Full Text] [Related]  

  • 25. uCyt+ test: alternative to cystoscopy for less-invasive follow-up of patients with low risk of urothelial carcinoma.
    Lodde M; Mian C; Comploj E; Palermo S; Longhi E; Marberger M; Pycha A
    Urology; 2006 May; 67(5):950-4. PubMed ID: 16698355
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Second resection and prognosis of primary high risk superficial bladder cancer: is cystectomy often too early?
    Brauers A; Buettner R; Jakse G
    J Urol; 2001 Mar; 165(3):808-10. PubMed ID: 11176474
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Watchful waiting policy in recurrent Ta G1 bladder tumors.
    Gofrit ON; Pode D; Lazar A; Katz R; Shapiro A
    Eur Urol; 2006 Feb; 49(2):303-6; discussion 306-7. PubMed ID: 16413659
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Cytoscopic follow-up of initial G3T1 bladder tumors treated with BCG].
    Pieras Ayala E; Palou J; Rodríguez-Villamil L; Millán Rodríguez F; Salvador Bayarri J; Vicente Rodríguez J
    Arch Esp Urol; 2001 Apr; 54(3):211-7. PubMed ID: 11432035
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Follow-up of patients with noninvasive and superficially invasive bladder cancer.
    Holmäng S
    Semin Urol Oncol; 2000 Nov; 18(4):273-9. PubMed ID: 11101090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-term follow-up of patients with Stage T1 high-grade transitional cell carcinoma managed by Bacille Calmette-Guérin immunotherapy.
    Margel D; Tal R; Golan S; Kedar D; Engelstein D; Baniel J
    Urology; 2007 Jan; 69(1):78-82. PubMed ID: 17270621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
    Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
    Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nomograms including nuclear matrix protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder.
    Shariat SF; Zippe C; Lüdecke G; Boman H; Sanchez-Carbayo M; Casella R; Mian C; Friedrich MG; Eissa S; Akaza H; Sawczuk I; Serretta V; Huland H; Hedelin H; Rupesh R; Miyanaga N; Sagalowsky AI; Wians F; Roehrborn CG; Lotan Y; Perrotte P; Benayoun S; Marberger MJ; Karakiewicz PI
    J Urol; 2005 May; 173(5):1518-25. PubMed ID: 15821471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intermediate-risk urothelial carcinoma: an unresolved problem?
    Pycha A; Lodde M; Comploj E; Negri G; Egarter-Vigl E; Vittadello F; Lusuardi L; Palermo S; Mian C
    Urology; 2004 Mar; 63(3):472-5. PubMed ID: 15028440
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
    Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
    BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
    Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lymphovascular invasion in transurethral resection specimens as predictor of progression and metastasis in patients with newly diagnosed T1 bladder urothelial cancer.
    Cho KS; Seo HK; Joung JY; Park WS; Ro JY; Han KS; Chung J; Lee KH
    J Urol; 2009 Dec; 182(6):2625-30. PubMed ID: 19836779
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled trial of short-term versus long-term prophylactic intravesical instillation chemotherapy for recurrence after transurethral resection of Ta/T1 transitional cell carcinoma of the bladder.
    Koga H; Kuroiwa K; Yamaguchi A; Osada Y; Tsuneyoshi M; Naito S
    J Urol; 2004 Jan; 171(1):153-7. PubMed ID: 14665865
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety of active surveillance program for recurrent nonmuscle-invasive bladder carcinoma.
    Hernández V; Alvarez M; de la Peña E; Amaruch N; Martín MD; de la Morena JM; Gómez V; Llorente C
    Urology; 2009 Jun; 73(6):1306-10. PubMed ID: 19375783
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical investigation for recurrence and progression in Ta grades 1 and 2 bladder cancer].
    Takei K; Kotake T; Masai M; Ito H; Nagao K; Chiba K; Saito K; Hirokawa M
    Hinyokika Kiyo; 1997 Mar; 43(3):185-9. PubMed ID: 9127752
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.